Trials / Unknown
UnknownNCT05955092
Exploring the Application of 3D Bioprinting for Personalized Treatment in Pancreatic Ductal Adenocarcinoma
Exploring the Application of 3D Bioprinting Technology in Constructing Preclinical Models of Pancreatic Cancer for Drug Sensitivity Testing and Its Significance in Personalized Treatment
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this observational study is to test the application value of 3D bioprinting technology in personalized treatment of pancreatic cancer. The main questions it aims to answer are: * Can 3D bioprinting technology be successfully applied to establish preclinical models of pancreatic cancer? * Can 3D bioprinted preclinical models of pancreatic cancer be applied to personalized treatment of pancreatic cancer? Participants will have tumor tissue collected to extract primary tumor cells for the establishment of in vitro preclinical models, which will be used for drug sensitivity testing.
Conditions
Timeline
- Start date
- 2022-12-01
- Primary completion
- 2024-06-30
- Completion
- 2024-09-30
- First posted
- 2023-07-21
- Last updated
- 2023-07-21
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05955092. Inclusion in this directory is not an endorsement.